Related Experiment Video
Updated: May 2, 2026
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
Anti-angiogenic therapy, a new player in the field of sarcoma treatment
Yvonne M H Versleijen-Jonkers1, Myrella Vlenterie1, Addy C M van de Luijtgaarden1
1Department of Medical Oncology, Radboud University Medical Center, Internal Postal Code 452, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
Abstract:
Sarcomas encompass a heterogeneous family of mesenchymal malignancies. In metastatic disease improvement in outcome has been limited and there is a clear need for the development of new therapies. One potential target is angiogenesis, already an accepted target for treatment of more prevalent cancers. Multiple (pre)clinical studies focused on the role of angiogenesis and anti-angiogenic treatment in sarcomas. However, getting significant results is complicated due to the relatively small number of patients and the broad range of sarcoma subtypes. Recently, pazopanib has been approved for the treatment of advanced soft tissue sarcoma patients, which is an important step forward and paves the way for the introduction of anti-angiogenic treatment in sarcomas. However, more studies are needed to understand the biological mechanisms by which patients respond to angiogenic inhibitors and to detect markers of response. This review covers the knowledge that has been gained on the role of angiogenesis and anti-angiogenic therapy in sarcomas.
Insights
This review explores angiogenesis and anti-angiogenic therapies for sarcomas, highlighting pazopanib
Area of Science:
- Oncology and Cancer Research
- Vascular Biology
Background:
- Sarcomas are rare mesenchymal malignancies with limited treatment options for metastatic disease.
- Angiogenesis is a validated therapeutic target in other cancers, prompting investigation in sarcomas.
Purpose of the Study:
- To review the current knowledge on the role of angiogenesis in sarcoma.
- To discuss the efficacy and challenges of anti-angiogenic therapies in sarcoma treatment.
Main Methods:
- Comprehensive literature review of preclinical and clinical studies on angiogenesis and anti-angiogenic agents in sarcomas.
- Analysis of the impact of pazopanib approval on sarcoma treatment paradigms.
Main Results:
- Angiogenesis plays a significant role in sarcoma progression.
- Clinical studies on anti-angiogenic agents in sarcomas have yielded complex results due to patient heterogeneity.
- Pazopanib represents a key advancement in treating advanced soft tissue sarcomas.
Conclusions:
- Anti-angiogenic therapy holds promise for sarcoma treatment.
- Further research is crucial to elucidate response mechanisms and identify predictive biomarkers for anti-angiogenic inhibitors in sarcomas.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:24Regulation of Angiogenesis and Blood Supply